Intravesical application of lidocaine and sodium bicarbonate in the treatment of obstructive, idiopathic lower urinary tract disease in cats by Zezza, Laura
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Intravesikale Applikation von Lidocain und Natriumbikarbonat bei der
Behandlung der obstruktiven, idiopathischen Erkrankung der unteren
Harnwege bei Katzen
Zezza, Laura
Abstract: Die idiopathische Erkrankung der unteren Harnwege der Katze (iLUTD) teilt viele Merkmale
mit der interstitiellen Zystitis (IC) des Menschen. Bei einigen Menschen mit IC wurde nach der in-
travesikalen Applikation von alkalisiertem Lidocain eine anhaltende Symptomlinderung festgestellt. Das
Ziel dieser Studie war, die Effekte der intravesikalen Instillation von alkalisiertem Lidocain in Bezug auf
Rezidivrate und Symptomlinderung bei obstruktiver iLUTD zu evaluieren. Zwölf Katzen wurden in die
Fallgruppe (2 oder 4mg/kg Lidocain und Natriumbikarbonat) und 14 in die Kontrollgruppe (Placebo
(0.2mL/kg 0.9% NaCl und Natriumbikarbonat) oder Standardtherapie (nur Harnkatheter, ohne Instil-
lation)) aufgenommen. Die Zuteilung zu den Gruppen erfolgte zufällig. Die Instillation wurde einmal
täglich für 3 Tage durchgeführt. Bei erfolgreicher Therapie wurde eine Nachkontrolle bis 2 Monate nach
Entlassung mittels Fragebogen durchgeführt. Die Rezidivrate betrug 58% (7/12) bei der Fallgruppe
und 57% (8/14) bei der Kontrollgruppe. Die Symptomlinderung war bei beiden Gruppen ähnlich. Bei
Katzen mit obstruktiver iLUTD hatte die intravesikale Applikation von Lidocain während drei Tagen
keine Auswirkung auf die Rezidivrate oder den Schweregrad der Symptome. Stichworte: idiopathische
Erkrankung der unteren Harnwege, Lidocain, interstitielle Zystitis.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-74602
Originally published at:
Zezza, Laura. Intravesikale Applikation von Lidocain und Natriumbikarbonat bei der Behandlung der
obstruktiven, idiopathischen Erkrankung der unteren Harnwege bei Katzen. 2012, University of Zurich,
Vetsuisse Faculty.
	   1	  
Index          Page 
 
 
 
Summary         2 
 
Introduction         3 
 
Materials and Methods       3 
 
Results         5 
 
Discussion         7 
 
Tables          9 
 
References         10 
 
Endnotes         12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   2	  
SUMMARY 
 
Vetsuisse Faculty University of Zürich (2012) 
 
Laura Zezza 
 
Clinic for Small Animal Internal Medicine, msekey@vetclinics.uzh.ch 
 
Intravesical application of lidocaine and sodium bicarbonate in the treatment of obstructive, 
idiopathic lower urinary tract disease in cats 
 
Idiopathic lower urinary tract disease (iLUTD) in cats shares many features in common with 
interstitial cystitis (IC) in humans. In human patients intravesical instillation of alkalinized 
lidocaine sometimes is associated with sustained amelioration of symptoms. The objective of 
this study was to evaluate whether the intravesical instillation of alkalinized lidocaine reduces 
recurrence of urethral obstructions and severity of clinical signs in cats with obstructive 
iLUTD. 
Twelve cats were included in the case group (2 or 4mg/kg lidocaine and sodium bicarbonate) 
and 14 cats served as controls (placebo (0.2mL/kg 0.9% NaCl and sodium bicarbonate) or 
standard therapy (urinary catheter only, without instillation)). Cats were randomly assigned to 
either group. The intravesical instillation was done once a day for 3 days. A follow-up of the 
cats with successful treatment was made up to 2 months after discharge using a questionnaire. 
Recurrence of urethral obstruction occurred in 58% (7/12) of the case group and 57% (8/14) 
of the control group. The amelioration scores were similar between the groups. 
The intravesical administration of alkalinized lidocaine for up to 3 days had no effects on 
recurrence and severity of clinical signs in cats with obstructive iLUTD. 
 
Keywords: idiopathic lower urinary tract disease, lidocaine, interstitial cystitis  
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INTRODUCTION 
 
The term feline lower urinary tract disease (LUTD) has been used to describe clinical signs 
related to irritative voiding, but does not identify the underlying etiology (Hostutler et al., 
2005; Forrester et al., 2007). The possible causes can include bacterial urinary tract infection, 
trauma, urolithiasis, urethral plugs, neoplasia, anatomic malformation, behavioral disorders 
and neurologic problems (Kruger et al., 2009; Hostutler et al., 2005). If no specific reason is 
found, the disease is called idiopathic (Westropp et al., 2004). Regardless of etiology, the 
resultant clinical signs are similar and include dysuria, stranguria, hematuria, pollakiuria and 
periuria (Forrester et al., 2007; Lekcharoensuk et al., 2001). The disorder can be obstructive, 
and urethral obstruction was reported to occur more commonly in young cats and almost 
exclusively in male cats due to their relatively long and narrow urethra (Hostutler et al., 
2005).  
Recurrence of obstruction is common. In 1 study, it was reported that 8 of 22 cats (36%) with 
idiopathic urethral obstruction re-obstructed after a median of 17 days (Gerber et al., 2008). In 
a more recent study, 11 of 55 cats (22%) with idiopathic obstructive LUTD experienced at 
least 1 recurrence in the 6 months after a previous episode (Segev et al., 2011). Currently, no 
treatment is known to decrease these high recurrence rates. 
A syndrome in human beings, known as interstitial cystitis (IC), shares many features in 
common with cats that have idiopathic cystitis (Buffington, 2011). The cause of IC also is 
unknown, and treatment is mostly empirical and unsatisfactory (Moutzouris et al., 2009). In a 
recent manufacturer funded study, treatment with intravesical alkalinized lidocaine (PSD597) 
and sodium bicarbonate in patients with IC was reported to provide amelioration of symptoms 
beyond the acute treatment phase (Nickel et al., 2009). IC is thought, in part, to develop into a 
visceral allodynia, as a result of sensitized local bladder afferent nerves (Butrick 2003). 
Theoretically, intravesical administration of the local anesthetic lidocaine could help control 
the pain and inflammation associated with IC, returning the neuropathic bladder to a more 
normal state with time (Nickel et al., 2009).  
Because of the positive effects of intravesical alkalinized lidocaine in affected humans, and 
the similarities reported between human IC and idiopathic LUTD in cats, we hypothesized 
that cats with LUTD might also benefit from intravesical lidocaine instillation. Because 
obstructive LUTD can become life threatening and urinary catheterization is necessary to 
relieve the obstruction, the study was only conducted on cats with urethral obstruction. The 
aim of this prospective study was to determine whether the intravesical instillation of 
lidocaine could effectively decrease the severity of clinical signs or the recurrence rate of 
urethral obstruction in cats with obstructive idiopathic LUTD. 
 
MATERIALS AND METHODS 
 
Case selection 
Cats presented to the Clinic for Small Animal Internal Medicine, University of Zurich, 
between July 2010 and September 2011 showing ≥1 of the following clinical signs: 
pollakiuria, hematuria, dysuria, stranguria, inappropriate urination and with partial or 
complete urethral obstruction were considered for the study. A cat was regarded as obstructed 
if the bladder was distended and the cat was unable to void urine freely or only voided drops 
of urine.  
Diagnostic investigation included history from the owner regarding previous episodes of 
LUTD and observed clinical abnormalities, a physical examination, urinalysis, urine culture, 
hematology, serum biochemistry profile, radiographs of the abdomen (care was taken to 
include the entire lower urinary tract to the tip of the penis) and ultrasound examination of the 
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urogenital tract. Urine was collected by cystocentesis or by catheterization. Qualitative urine 
culture was performed on sheep blood agar, Gassner agar and Clad agar1. If there was 
suspicion of urethral stricture or perforation of the lower urinary tract, contrast radiography 
(retrograde uretrography) also was performed.  
Urolithiasis was diagnosed when calculi were seen on radiographs or during ultrasound 
examination of the urinary tract. Urinary tract infection was diagnosed when qualitative urine 
culture was positive. Urethral plug was diagnosed when a plug was identified during urethral 
catheterization. If the underlying cause of the obstruction could not be identified after 
appropriate evaluation, idiopathic LUTD was diagnosed. Only cats with the idiopathic LUTD 
were enrolled in the study. Owner consent was obtained before treatment with lidocaine. The 
government animal welfare authorities of the canton of Zurich, Switzerland approved the 
treatment protocol used in the study. 
 
Procedure 
After diagnostic investigation and confirmation of urethral obstruction, IV fluid therapy was 
started. Urethral obstruction was relieved in a standard manner. Cats were anesthetized with 
fentanyl2 (5 µg/kg IV) and midazolam3 (0.23 mg/kg IV) or ketamine4 (10 mg/kg IV (for 
anesthetic induction) or IM (for deep sedation)) and midazolam (0.1 mg/kg IV or IM) and 
maintained under anesthesia with IV injection of propofol5 or with inhalation anesthesia 
(isofloran6) until an indwelling urinary catheter7 was placed and sutured to the prepuce. When 
feasible, the urinary catheter was kept in place for 3 days. The urinary catheter was connected 
to a sterile closed collection system8 to keep the bladder empty and to quantify urine 
production. Cats were concurrently treated with an analgesic (buprenorphine9 0.006-0.014 
mg/kg IV q6h) and fluid was administered IV (lactated Ringer’s solution or 0.9% saline 
solution)10. The initial infusion rate was determined based on the hydration status and physical 
condition of the cat at presentation. The rate was adjusted daily based on urine production 
assessed during the day.  
The first 12 cats were treated by intravesical lidocaine instillation11, 0.1 mL/kg of a 2% 
lidocaine solution, a dosage reported to be safe after IV administration in a recent study (Ko 
JC et al., 2008). Sodium bicarbonate12, 0.06 mL/kg of an 8.4% solution, was added 
immediately afterward. Because no adverse effects were seen and serum concentrations were 
low, we increased the amount of lidocaine in the solution. Subsequently, the next cats were 
randomly assigned to receive intravesical either 0.2 mL/kg of a 2% lidocaine solution or 
placebo (0.2 mL/kg of a 0.9% saline solution) and 0.06 mL/kg of an 8.4% sodium bicarbonate 
solution, respectively. If the owners declined to enroll their cats in the study or if the cats 
were too aggressive and uncooperative at the beginning of treatment, the cats were treated 
according to a standard procedure (3 days with an indwelling urinary catheter but without 
intravesical instillation).  
The case group consisted of cats that received the intravesical medication of either 0.1 or 0.2 
mL/kg of a 2% lidocaine solution and 0.06 mL/kg of an 8.4% sodium bicarbonate solution. 
The control group consisted of cats that either received intravesical instillation of 0.2 mL/kg 
placebo (equal to the volume of the instilled 2% lidocaine solution) and 0.06 mL/kg of an 
8.4% sodium bicarbonate solution or those that underwent the standard treatment. Before 
instillation, the bladder was emptied and, after instillation, the urinary catheter was closed for 
1 hour to allow the medication to remain in place. After 1 hour, the catheter was re-attached 
to the closed urine collection system and urine production was assessed. This procedure was 
performed once a day for a maximum of 3 consecutive days. 
After removal of the urinary catheter, presence of spontaneous urination was assessed by 
monitoring the cats every 2 hours for up to 2 days. Antibacterial treatment with amoxicillin-
clavulanic acid13 (20 mg/kg PO q12h) or amoxicillin14 (20 mg/kg PO q12h) was started 
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concurrently and continued in cats that did not re-obstruct immediately after removal of the 
urinary catheter. 
Treatment success was defined as spontaneous urination (normal urine stream and empty 
bladder after voiding) and discharge from the hospital. Buprenorphine (0.006-0.014 mg/kg 
PO q8h) or meloxicam suspension15 (0.025 mg/kg PO q24h) in cats with and without 
azotemia at presentation, respectively, was prescribed for 3 additional days after discharge. 
The antibacterial treatment was continued for 1 week. Follow-up of cats with successful 
treatment was made 2 weeks, 1 month and 2 months after discharge using a questionnaire to  
assess the severity of the clinical signs after therapy. 
Treatment failure was defined as failure to have spontaneous urination (i.e., unable to urinate 
or only voiding drops of urine with a distended bladder). These cats were excluded from 
follow-up assessment. Their owners were asked to complete only the questionnaire for the 
clinical signs before treatment. A modification of a previously used questionnaire (Gunn-
Moore et al., 2004) was used. All questionnaires were composed of 8 visual analogue scales, 
each 10 cm in length, with values ranging from 0 (normal cat) to 10 (very severe clinical 
signs). The 8 signs the owners were asked to record were: (1) increased frequency of 
urination, (2) straining while urinating, (3) crying out while urinating, (4) presence of blood in 
the urine (macroscopic hematuria), (5) urination outside the litter box, (6) increased grooming 
around the perineum, (7) altered behavior (increased aggression, fear, or nervousness) and (8) 
gastrointestinal symptoms (e.g., vomiting, or diarrhea). 
The primary endpoint was the recurrence of urethral obstruction within 2 months after 
removal of the catheter. The recurrence rate between groups was assessed and compared.  
A secondary endpoint included the assessment of changes in severity (amelioration) of 
clinical signs of LUTD from baseline (before treatment), 2 weeks, 1 month and 2 months after 
discharge in cats with successful treatment. Because of the subjectivity of the questionnaire, 
the median change from baseline (median amelioration scores) for individual clinical signs 
and the sum of the 8 scales were calculated at each time point. Differences between the 
groups were compared. The questionnaire for the time before treatment was performed before 
or at least on the same day of discharge.  
 
Serum lidocaine concentrations and tolerability 
Blood samples for the evaluation of plasma lidocaine concentrations were collected from 2 
cats treated with 0.1 mL/kg of 2% lidocaine and 2 cats treated with 0.2 mL/kg of 2% 
lidocaine at time 0 h (immediately after instillation), 0.5 h, 1 h, 2 h and 3 h after treatment on 
2 consecutive days of therapy. Plasma lidocaine concentrations were measured using high 
performance liquid chromatography-mass spectrometry. Any clinical signs of adverse effects 
related to lidocaine toxicity were monitored and recorded every 2 hours during 
hospitalization.  
 
Statistical analysis 
Results were analyzed using a commercial computer program (Statistical Package for Social 
Science 8.0; SPSS). Because of the small simple size, especially in the follow up assessment, 
comparisons of variables within and among groups were performed using a non-parametric 
test (the Mann-Whitney U test). Statistical analysis was not conducted if < 4 results were 
available to compare. Differences were considered significant at p<0.05.  
 
RESULTS 
 
Overall, 69 cats were presented to the Clinic for Small Animal Internal Medicine, University 
of Zurich between July 2010 and September 2011 because of lower urinary tract signs with 
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urethral obstruction. Thirty-four cats were excluded from the study because of urolithiasis 
(=13, 19%), urethral plugs (=5, 7%) and urinary tract infection (=14, 20 %). In 2 cats (3%), a 
definitive diagnosis was not possible because not all of the diagnostic investigations could be 
made. These 2 cats also were excluded from the study. In 35 cats (51%), no specific cause for 
the clinical signs could be identified. These cats were classified as having idiopathic 
obstructive LUTD. Of these 35 cats, 9 were excluded because of immediate surgery (perineal 
urethrostomy, 6 cats), urethral perforation after catheterization (1 cat) and euthanasia 
requested by the owner (2 cats). Twenty-six cats (38%) remained in the study. 
 
The cats included in the study ranged in age from 1 to 9 years (median, 5 years) and weighed 
between 3.8 and 7.2 kg (median, 5.5 kg). There were 25 neutered males and 1 intact male. 
The breeds included 20 domestic cats, 2 Persians, 1 Main Coon, 1 Siamese and 2 Siberian 
Forest cats. Blood urea nitrogen (BUN) serum, creatinine and serum potassium concentration 
ranged between 5.5 and 138 mmol/L (median, 12.6 mmol/L), 70 and 1700 µmol/L (median, 
150.5 µmol/L) and 2.8 and 8.6 mmol/L (median, 4.5 mmol/L), respectively. The present 
episode was the first known episode of LUTD for 21 cats whereas recurrent bouts were 
described for the 5 other cats. Twelve cats were treated with 2% lidocaine (4 cats with 0.1 
mL/kg and 8 cats with 0.2 mL/kg). Fourteen cats were in the control group (8 cats were 
treated with placebo and 6 cats with standard therapy). There was no significant difference in 
age, breed, BUN serum, creatinine, serum potassium concentration, or number of LUTD 
episodes between groups. Body weight was significantly higher in the case group (p=0.04). 
Clinical signs scores available from 10 cats in the case group and 12 cats in the control group 
before treatment were not significantly different between the 2 groups (Table 1). In 3 cats 
treated with 0.2 mL/kg 2% lidocaine and in 1 cat treated with placebo, intravesical instillation 
was possible only for 2 days because of self-removal of the catheter after 2 days of therapy. In 
1 cat treated with 0.2 mL/kg 2% lidocaine, intravesical treatment was possible only for 1 day 
because of the aggressive behavior of the cat after the first day of therapy. Median treatment 
duration in both groups was 3 days. All of the cats experienced post-obstructive diuresis after 
relief of obstruction. In 24 cats, the highest daily urine production was assessed, and ranged 
between 2.2 and 12.0 mL/kg/h (median, 6 mL/kg/h). Additionally, in 5 of the 26 cats, urine 
pH was measured at 1 hour immediately before re-attaching the urinary catheter to the 
collection system. Urine pH was 6, 7.5, 8.5 in 3 cats and 8 in other 2 cats. 
Recurrence of urethral obstruction after removal of the urethral catheter was 58% (7/12) in the 
case group 50% (2/4) in cats that received 0.1 mL/kg 2% lidocaine, 63% (5/8) in cats that 
received 0.2 mL/kg 2% lidocaine within 1 to 14 days (median, 3 days) and 57% (8/14) in the 
control group (63% in 5/8 cats in the placebo group and 50% in 3/6 cats that received 
standard therapy) within 1 to 2 days (median, 1 day). Five cats in the case group and 6 cats in 
the control group had successful treatment for at least 2 months after discharge. These 11 cats 
were followed up for assessment of amelioration of clinical signs. Of all 11 questionnaires 
sent to the owners at each of 3 time points (2 weeks, 1 month and 2 months after discharge), 
10 (4 of the case group and 6 of the control group), 10 (4 of the case group and 6 of the 
control group) and 9 (4 of the case group and 5 of the control group) were returned, 
respectively. The owners who did not return questionnaires were contacted by phone to assess 
recurrence. In the case group, the degree of severity in frequency of urination was not 
recorded in 1 questionnaire before treatment as well as in another cat 2 weeks and 2 months 
after treatment. For these clinical signs, 2 weeks and 2 months after treatment, the available 
results were insufficient to allow statistical analysis.  
Cats treated with lidocaine showed significantly higher median amelioration score in straining 
2 weeks after discharge compared to the cats in the control group (p=0.01). There were no 
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significant differences between groups in the other individual clinical signs as well as in the 
sum of the scores at any time point. 
 
Serum lidocaine concentrations and tolerability  
In all cats, lidocaine concentrations peaked within 60 minutes of instillation, ranging between 
0.45 and 4.1 µmol/L (Table 2). In all 4 cats, blood sampling was not possible at all 5 time 
points. No severe adverse events were reported during intravesical therapy. One cat treated 
with 0.2 mL/kg 2% lidocaine experienced 1 episode of salivation on the third day of 
treatment. 
 
DISCUSSION 
 
The response of cats with idiopathic obstructive LUTD to lidocaine treatment with regard to 
recurrence and amelioration of clinical signs was poor. Within the 1-year trial period, 
recurrence of urethral obstruction was seen in 58% of the cats in the case group and in 57% of 
cats in the control group within 2 months. In a previous 1-year study, cats with idiopathic 
obstructive LUTD experienced a recurrence rate of only 22% within 6 months (Segev et al., 
2010). It is unclear why the cats in the current study showed more recurrence of the disease, 
and may reflect the different definition used to describe the obstruction. In particular, in the 
current study a cat was defined as obstructed if it was unable to generate a normal stream of 
urine (i.e., only voided drops of urine) with a distended bladder. It also could be that the 
observation of the clinicians and the owners was closer because of the prospective study 
design and led to the recognition of even mild partial obstruction. Furthermore, idiopathic 
LUTD was diagnosed by exclusion of other possible causes and, as discussed in a previous 
study, a specific cause potentially could have been overlooked. For example, a plug may not 
have been seen and may have been retropulsed into the bladder after placement of the urinary 
catheter, leading to a misdiagnosis of idiopathic LUTD (Gerber et al., 2008). Furthermore, 
retrograde urethrography was only performed when leakage of the lower urinary tract was 
suspected. Anatomic malformations and strictures could not definitively be excluded in the 
cats in which urethrography was not performed. 
A significant difference between groups in the follow-up assessment was only observed in 
amelioration of straining 2 weeks after discharge. This significance may only be the 
consequence of statistical analysis conducted for several clinical signs all reflecting the same 
disease (type I statistical error). However, it might also reflect a limited potential effect of 
lidocaine, inducing only relief from pain while urinating (stranguria) without inducing an 
adequate local anti-inflammatory effect. Lidocaine is primarily recognized as a neuronal 
sodium channel-blocking agent, but it also has proprieties capable of substantial 
antihistaminic effects. In an in vitro study, these effects were reported to be dose-dependent 
and at concentrations in the high micromolar range (234 to 2340 µg/mL or 1000 to 10000 
µmol/L, respectively) (Yanagi et al., 1996). A low serum lidocaine concentration may be 
sufficient to generate a neuronal sodium-blocking effect (i.e., pain relief), whereas a very high 
tissue lidocaine concentration may be necessary to achieve antihistaminic effects (i.e., anti-
inflammatory effect). The lack of a demonstrable relevant beneficial effect could be related to 
subtherapeutic treatment because of an inadequate dosage of lidocaine or sodium bicarbonate, 
inadequate duration of the treatment, or because of the small sample size and insufficient 
power. 
It is well known that cats may be more sensitive than other species to the toxic effects of local 
anesthetics, in particular to central nervous system effects (Plumb 1999). However, the 
cumulative doses of lidocaine in healthy cats were reported to be 9.7 mg/kg at the stage of 
excitation and 22.3 – 27.3 mg/kg for the induction of convulsions (Seo et al., 1982). The 
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plasma lidocaine concentration associated with the onset of seizures was reported to be 
between 71.3 and 208.5 µg/mL (304.8 - 891.3 µmol/L) (Chadwick, 1985). Because adverse 
effects also have been observed after IV application of < 2 mg/kg lidocaine (Tilley et al., 
1977) and because cats with cystitis have increased bladder permeability (Gao et al., 1994), 
the first cats of the current study were treated with a dose of 0.1 mL/kg of a 2% lidocaine 
solution. The serum lidocaine concentration was assessed in 2 of these cats. The concentration 
was well below to the plasma concentration reported to be associated with the onset of 
seizures, and the cats did not show any obvious adverse effects. Therefore, the next cats were 
treated with a higher dose (0.2 mL/kg of a 2% solution) and even with this dose a critical 
concentration was not reached. Only 1 cat showed 1 episode of salivation on the third day of 
the lidocaine treatment. This cat exhibited signs of stress, and the new environment may have 
contributed to the salivation. Previous studies conducted in humans demonstrated poor 
absorption of lidocaine from the bladder and poor local therapeutic effects if only applied 
intravesically (Pode et al., 1992; Birch et al., 1994). Enhanced absorption and therapeutic 
effects were reported after alkalinizing the injected solution with sodium bicarbonate (Henry 
et al., 2001; Parsons 2005). Therefore, a sequential instillation of 0.06 mL/kg sodium 
bicarbonate was added in all the cats receiving intravesical medication. However, voided 
bladder content pH 1 hour after application was not alkaline in all the 5 cats in which it was 
measured. Furthermore, the lidocaine concentration in serum differed considerably among 
cats. A possible explanation could be the phenomenon of post-obstructive diuresis (urine 
output > 2 mL/kg/h (Francis et al., 2010)). This pathophysiologic process could lead to 
dilution of urine, alteration of urine pH and reduction of the bladder lidocaine concentration 
within 1 hour after application. A longer duration of treatment also may have influenced the 
outcome. In studies of patients with IC, an immediate and sustained symptomatic relief 
beyond the treatment phase was reported after 5 consecutive days of lidocaine instillations 
(Nickel et al., 2008) as well as after 6 instillations over 2 weeks (Parsons, 2005). Because the 
risk of physical or chemical injury to the urinary tract and bacterial infections has been 
reported to increase with the duration of catheterization (Barsanti et al., 1985; Lees et al.,  
1984), therapy in the current study was limited to 3 days. 
 
Important weaknesses of the study are the small sample size, in particular in the follow-up 
assessment. Furthermore, because of the uncooperative behavior of some cats, intravesical 
instillation was not always possible for 3 consecutive days. Moreover, only cooperative and 
non-aggressive cats as well as cats of owners who wanted to participate were randomly 
assigned to the study groups. Furthermore, because written consent by the owners of the cats 
treated with lidocaine was requested, we decided not to blind owners to the treatments used. 
These attendant circumstances could have biased our results.  
 
In conclusion, the current study shows an alternative procedure for the treatment of idiopathic 
cystitis in cats with urethral obstruction. The results suggest that intravesical administration of 
lidocaine (0.1 or 0.2 mL/kg of a 2% solution) and sodium bicarbonate (0.06 mL/kg) for 3 
consecutive days does not have apparent beneficial effects on decreasing the recurrence of 
obstruction as well as on clinical signs in cats with idiopathic obstructive LUTD.  
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TABLES 
 
Table 1 - Median and range of the clinical signs score prior to treatment (baseline score) in 
the case (10 cats) and in the control group (12 cats)  
 
Clinical signs Group Baseline 
Case 5 (1 to 10) Increased frequency of urination 
Control 8 (0 to 10) 
Case 7.5 (1 to 10) Straining while urinating 
Control 7 (1 to 10) 
Case 0 (0 to 8) Crying out while urinating 
Control 1 (0 to 10) 
Case 1 (0 to 10) Presence of blood in the urine 
Control 1 (0 to 10) 
Case 8 (0 to 10) Urination outside the litter box 
Control 7 (0 to 10) 
Case 6 (2 to 10) Increased grooming around the perineum 
Control 7 (0 to 10) 
Case 5.5 (0 to 10) Altered behavior 
Control 6.5 (0 to 10) 
Case 1.5 (0 to 10) Gastrointestinal symptoms 
Control 1 (0 to 10) 
Case 39 (14 to 51) Sum 
Control 43 (9 to 75) 
 
 
Table 2 - Plasma lidocaine concentrations (µmol/L) and post-obstructive diuresis (mL/kg/h) at 
2 consecutive days after intravesical lidocaine application in 4 cats. 
 
 0.1 mL/kg 2% lidocaine 0.2 mL/kg 2% lidocaine 
 Cat I Cat II Cat III Cat IV 
Hours (h) Day 1 Day 2 Day 2 Day 3 Day 1 Day 2 Day 1 Day 2 
0 - <0.10 - 4.07 - <0.10 - - 
0.5 - 1.57 2.48 2.71 0.48 0.45 0.96 1.64 
1 1.34 1.45 1.36 - 0.51 - 0.93 2.46 
2 - - 0.79 1.20 - 0.35 0.42 0.92 
3 0.65 0.87 0.64 0.79 0.24 - 0.30 0.30 
POD 4.6 4.2 6.3 5.3 6.6 6.6 8.0 7.5 
             Highest serum lidocaine concentration of all collected blood samples per cat and day 
POD, post-obstructive diuresis 
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